Unravelling the molecular interactions driving Alzheimer’s disease
Dr Vanessa Morris of the University of Canterbury will investigate the interaction between Alzheimer’s disease and the immune system protein TREM2
Published on 5 November 2019
Alzheimer’s disease is the most common form of dementia and a leading cause of death worldwide. It affects nearly 1.3% of the population in Aotearoa. Due to our ageing population, the rates of Alzheimer’s disease are increasing. While current treatments can help to manage symptoms, they are unable to slow the progression of this devastating disease, which gradually leads to loss of most brain functions and ultimately the death of the patient.
Two hallmarks of Alzheimer’s disease progression are abnormal accumulation of the ‘amyloid-beta’ protein within brain cells and inflammation of brain tissue. Recent genetic research suggests that the TREM2 gene is associated with inflammation and protein accumulation linked to Alzheimer’s disease. Moreover, people who carry rare mutations in TREM2 are three times more likely to develop Alzheimer’s disease later in life. This makes TREM2 one of the strongest risk factors for Alzheimer’s disease identified to date.
With her Te Pūtea Rangahau a Marsden Fast-Start grant, Dr Morris will use molecular and biophysical techniques to determine how ‘amyloid-beta’ protein aggregates interact with TREM2. She will then determine how disease-linked mutations affect this interaction, and the molecular basis by which they confer increased Alzheimer’s disease risk. This work will establish crucial information on the molecular pathology of Alzheimer’s disease, seek urgently needed insights into the mechanisms of disease progression, and pave the way for the development of therapies to modulate these key protein interactions in Alzheimer’s disease.